To bring AI-powered cancer detection and monitoring to India
C2i Genomics announced a strategic partnership with Karkinos Healthcare, a technology-led managed care platform for cancer, to co-develop the minimal residual disease (MRD) market in India. The partnership enables C2i Genomics to bring innovative cancer detection technology to drive R&D, future pharma partnerships and clinical use in India and supports the company’s long-term goals to scale pharma R&D projects around the globe. The partnership will expand MRD monitoring within the Karkinos’ health system and its partners using the C2i Genomics’ ultrasensitive whole-genome analysis.
“Since founding C2i Genomics our team has been laser-focused on making sophisticated AI-informed cancer diagnostics and tumour monitoring available throughout the world, regardless of where patients or clinical trials are located,” said Asaf Zviran, CEO and co-founder, C2i Genomics. “Karkinos Healthcare shares in our vision to increase access to distributed cancer monitoring and will be instrumental in advancing our commercialisation efforts to bring the C2inform MRD test to labs across India.”
The C2inform MRD test enables physicians to trace small amounts of persistent or recurrent cancer much earlier and at far lower levels than currently available technologies. C2i Genomics’ SaaS solution utilises a cloud-based platform to perform cancer tumour burden monitoring on a global scale, utilising equipped labs and sequencing networks worldwide. By using machine learning and AI technology to analyze patients’ blood for early detection of cancer recurrence or resistance, C2i Genomics directly drives more informed treatment decisions and personalised treatment plans.
”At Karkinos, we are combining best-in-class oncology expertise with advances in technology and biosciences to promote early detection of cancer,“ said R Venkataramanan, CEO and founder, Karkinos Healthcare. ”Our partnership with C2i Genomics will enable cancer patients in India to benefit from the MRD test which will be available through our Advanced Center for Cancer Diagnostics and Research at Kochi.”
